var data={"title":"Cefepime: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefepime: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5838?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefepime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefepime: Patient drug information&quot;</a> and <a href=\"topic.htm?path=cefepime-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefepime: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452476\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Maxipime</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147316\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Maxipime</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147353\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Cephalosporin (Fourth Generation)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147319\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Febrile neutropenia:</b> IV: 2 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infections, complicated, severe (in combination with metronidazole):</b> IV: <b>Note:</b> 2010 IDSA guidelines recommend a duration of 4 to 7 days (provided source controlled). Not recommended for hospital-acquired intra-abdominal infections (IAI) associated with multidrug-resistant gram negative organisms or in mild-to-moderate community-acquired IAIs due to risk of toxicity and the development of resistant organisms (Solomkin [IDSA] 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Due to <i>P. aeruginosa: </i> 2 g every 8 hours for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Not due to <i>P. aeruginosa: </i> 2 g every 8 to 12 hours for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia: </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Due to <i>P. aeruginosa: </i> 2 g every 8 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Not due to <i>P. aeruginosa: </i> 1 to 2 g every 8 to 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing: </i>Hospital-acquired or ventilator-associated: 2 g every 8 hours for 7 days; may consider shorter or longer duration depending on rate of clinical improvement. Administration as an extended infusion may be considered. When used as empiric therapy, use in combination with an agent active against MRSA (unless coverage of MSSA only is appropriate) with or without an additional antipseudomonal agent (dependent on patient and institution-specific risk factors) (Kalil 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infection, uncomplicated (moderate to severe): </b> IV: 2 g every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections, complicated and uncomplicated:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mild-to-moderate</i>: IM, IV: 0.5 to 1 g every 12 hours for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe</i>: IV: 2 g every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial meningitis (off-label use): </b> IV: 2 g every 8 hours duration of therapy varies depending on pathogen (IDSA [Tunkel 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis, native vertebral (off-label use) (IDSA [Berbari 2015]): </b>IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>P. aeruginosa: </i>2 g every 8 to 12 hours for 6 weeks. <b>Note: </b>Double coverage may be considered (ie, cefepime plus an aminoglycoside or ciprofloxacin).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Enterobacteriaceae: 2 g every 12 hours for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection, <i>Enterobacter spp. </i> or <i>Pseudomonas aeruginosa </i> (off-label use): </b> IV: 2 g every 12 hours for 4 to 6 weeks. <b>Note:</b> When treating <i>P. aeruginosa</i>, consider addition of an aminoglycoside (Osmon 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147337\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cefepime-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefepime: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate infection: 50 mg/kg/dose every 12 hours; maximum dose: 2,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe infection: 50 mg/kg/dose every 8 to 12 hours; maximum dose: 2,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, prosthetic valve, treatment within 1 year of replacement (off-label use):</b> Children and Adolescents: IV: 50 mg/kg/dose every 8 to 12 hours in combination with vancomycin and rifampin for 6 weeks plus gentamicin for the first 2 weeks; maximum dose: 2,000 mg/dose (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Febrile neutropenia:</b> Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours (maximum dose: 2,000 mg/dose) (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia:</b> Infants &ge;2 months, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Due to <i>P. aeruginosa: </i> 50 mg/kg/dose every 8 hours for 10 days (maximum dose: 2,000 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Not due to <i>P. aeruginosa: </i> 50 mg/kg/dose every 12 hours for 10 days (maximum dose: 2,000 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections (uncomplicated):</b> Infants &ge; 2 months, Children, and Adolescents: IV: 50 mg/kg/dose every 12 hours for 10 days (maximum dose: 2,000 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections, complicated and uncomplicated:</b> Infants &ge; 2 months, Children, and Adolescents: IV, IM: <b>Note:</b> IM may be considered for mild to moderate infection only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mild to moderate infection:</i> IV, IM: 50 mg/kg/dose every 12 hours for 7 to 10 days (maximum dose: 1,000 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe infection:</i> IV: 50 mg/kg/dose every 12 hours for 10 days (maximum dose: 2,000 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection, complicated (off-label):</b> Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 12 hours in combination with metronidazole (maximum dose: 2,000 mg/dose). <b>Note:</b> IDSA 2010 guidelines recommend duration of 4 to 7 days (provided source controlled) (Solomkin [IDSA] 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147320\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147321\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: Recommended maintenance schedule based on creatinine clearance (may be estimated using the Cockcroft-Gault formula), compared to normal dosing schedule: See table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Cefepime Hydrochloride</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Creatinine Clearance</p>\n            <p style=\"text-indent:0em;\">(mL/minute)</p></th>\n          <th colspan=\"4\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Recommended Maintenance Schedule</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;60</p>\n            <p style=\"text-indent:0em;\">(normal recommended dosing schedule)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 mg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 g every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 g every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 g every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30-60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 g every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 g every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 g every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11-29</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 g every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 g every 24 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;11</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 mg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 g every 24 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): IV: Initial: 1 g (single dose) on day 1. Maintenance: 0.5-1 g every 24 hours<b> or</b> 1-2 g every 48-72 hours (Heintz 2009) <b>or</b> 2 g 3 times weekly after dialysis (Perez 2012). <b>Note:</b> Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis (PD): Removed to a lesser extent than hemodialysis; administer normal recommended dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVH: Loading dose of 2 g followed by 1-2 g every 12 hours</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">CVVHD/CVVHDF: Loading dose of 2 g followed by either 1 g every 8 hours <b>or</b> 2 g every 12 hours. <b>Note:</b> Dosage of 1 g every 8 hours results in similar steady-state concentrations as 2 g every 12 hours and is more cost effective (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Consider higher dosage of 4 g/day if treating <i>Pseudomonas</i> or life-threatening infections in order to maximize time above MIC (Trotman 2005). Dosage of 2 g every 8 hours may be needed for gram-negative rods with MIC &ge;4 mg/L (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Infants &ge; 2 months, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, similar dosage adjustments to adults would be anticipated based on comparable pharmacokinetics between children and adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682524\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147294\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/50 mL (50 mL); 2 g/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maxipime: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maxipime: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/50 mL (1 ea); 2 g/50 mL (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147278\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147298\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered either IM or IV</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Inject deep IM into large muscle mass.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer as an intermittent infusion over 30 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Off-label:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Direct IV: Inject direct IV over 5 minutes (Garrelts 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended infusion: In certain patients where extended infusions may be appropriate, doses are usually infused over 3 to 4 hours (Bauer 2013; Nicasio 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147297\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Febrile neutropenia:</b> Empiric treatment of febrile neutropenic patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infections:</b> Treatment of complicated intra-abdominal infections, in combination with metronidazole, caused by <i>Escherichia coli</i>, viridans group streptococci, <i>Pseudomonas aeruginosa</i>, <i>Klebsiella pneumoniae</i>, <i>Enterobacter</i> species, or <i>Bacteroides fragilis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia (moderate to severe):</b> Treatment of moderate to severe pneumonia caused by <i>Streptococcus pneumoniae</i>, including cases associated with concurrent bacteremia, <i>P. aeruginosa</i>, <i>K. pneumoniae</i>, or <i>Enterobacter</i> species.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Treatment of moderate to severe uncomplicated skin and skin structure infections caused by <i>Staphylococcus aureus</i> (methicillin-susceptible isolates only) or <i>Streptococcus pyogenes</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections (including pyelonephritis):</b> Treatment of complicated and uncomplicated urinary tract infections, including pyelonephritis, caused by <i>E. coli</i> or <i>K. pneumoniae</i>, when the infection is severe, or caused by <i>E. coli</i>, <i>K. pneumoniae</i>, or <i>Proteus mirabilis</i>, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25595582\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bacterial meningitis; Endocarditis, prosthetic valve, treatment within 1 year of replacement (pediatric); Osteomyelitis, native vertebral; Prosthetic joint infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9645319\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cefepime may be confused with cefixime, cefTAZidime</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147285\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: Hematologic &amp; oncologic: Positive direct Coombs test (without hemolysis; 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Localized phlebitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (1% to 4%), pruritus (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypophosphatemia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (&le;3%), nausea (&le;2%), vomiting (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Eosinophilia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum ALT (3%), abnormal partial thromboplastin time (2%), increased serum AST (2%), abnormal prothrombin time (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity (in patients with a history of penicillin allergy: &le;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, anaphylactic shock, anaphylaxis, anemia, aphasia, brain disease, <i>Clostridium difficile</i> associated diarrhea, colitis, coma, confusion, decreased hematocrit, erythema, hallucination, hypercalcemia, hyperkalemia, hyperphosphatemia, hypocalcemia, increased blood urea nitrogen, increased serum alkaline phosphatase, increased serum bilirubin, increased serum creatinine, leukopenia, local inflammation, local pain, myoclonus, neurotoxicity, neutropenia, oral candidiasis, pseudomembranous colitis, seizure, status epilepticus (nonconvulsive), stupor, thrombocytopenia, urticaria, vaginitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147301\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefepime, other cephalosporins, penicillins, other beta-lactam antibiotics, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147282\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: May occur; use caution in patients with a history of penicillin sensitivity; cross-hypersensitivity may occur. If a hypersensitivity reaction occurs, discontinue therapy and institute supportive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Severe neurological reactions (some fatal) have been reported, including encephalopathy, aphasia, myoclonus, seizures, and nonconvulsive status epilepticus. Risk may be increased in the presence of renal impairment; ensure dose adjusted for renal function and discontinue therapy if patient develops neurotoxicity; effects are often reversible upon discontinuation of cefepime.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (CrCl &le;60 mL/minute); dosage adjustments recommended. May increase risk of encephalopathy, myoclonus, and seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Serious adverse reactions have occurred in elderly patients with renal insufficiency given unadjusted doses of cefepime, including life-threatening or fatal occurrences of encephalopathy, myoclonus, and seizures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298988\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147287\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9215&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (4th Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147290\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5947925\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Cefepime crosses the placenta.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147303\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Small amounts of cefepime are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefepime to nursing women. Nondose-related effects could include modification of bowel flora.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147292\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147281\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysis and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147300\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: IM: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates (Capparelli, 2005):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PMA &lt;30 weeks: 0.51 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PMA &gt;30 weeks: 0.39 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 2 months to 11 years: 0.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 18 L, 0.26 L/kg; penetrates into inflammatory fluid at concentrations ~80% of serum concentrations and into bronchial mucosa at concentrations ~60% of plasma concentrations; crosses the blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding, plasma: ~20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minimally hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 4 to 5 hours (Lima-Rogel 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 months to 6 years: 1.77 to 1.96 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: 13.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous peritoneal dialysis: 19 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: IM: 1 to 2 hours; IV: 0.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (85% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323046\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cefepime HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (50 mL): $31.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/100 mL (100 mL): $51.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cefepime HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $6.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $11.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cefepime-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (1): $13.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 gm/50 mL (1): $20.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Maxipime Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $6.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $10.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Maxipime Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $6.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $11.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147304\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abypym (UA);</li>\n      <li>Acedrin (PY);</li>\n      <li>Alcemax (PH);</li>\n      <li>Amfapime (VN);</li>\n      <li>Axepim (FR);</li>\n      <li>Axera (PH);</li>\n      <li>Biocepime (ID);</li>\n      <li>Caprifim (ID);</li>\n      <li>Cefamax (TH);</li>\n      <li>Cefemax (TW);</li>\n      <li>Cefemet (ID);</li>\n      <li>Cefepima (CO);</li>\n      <li>Ceficad (IN);</li>\n      <li>Cefinov (ID);</li>\n      <li>Cefipex (LB);</li>\n      <li>Cefpas (LK);</li>\n      <li>Cepiram (PH);</li>\n      <li>Deltacef (TR);</li>\n      <li>Dimipra (PH);</li>\n      <li>Epime (LK);</li>\n      <li>Exepime (ID);</li>\n      <li>Falocef (ID);</li>\n      <li>Forgen (BD);</li>\n      <li>Forzyn Beta (PY);</li>\n      <li>Funjapin (TW);</li>\n      <li>Imation (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Interprim (ID);</li>\n      <li>Kuadrotsef (UA);</li>\n      <li>Macef (ID);</li>\n      <li>Macepim (TW);</li>\n      <li>Maxcef (AR, BR, CR, DO, GT, HN, LK, NI, PA, SV, UY);</li>\n      <li>Maxef (MX);</li>\n      <li>Maxfrom (AR);</li>\n      <li>Maxicef (ID, LK);</li>\n      <li>Maxilan (ID);</li>\n      <li>Maxipime (AE, AT, BB, BE, BG, BH, CH, CL, CN, CZ, DE, DK, EC, EE, EG, ES, FI, GR, HK, HR, HU, IT, JO, JP, KR, KW, LB, LT, LU, MX, MY, NL, PE, PK, PL, PT, QA, RU, SA, SE, SG, SI, SK, TR, TW, VE, VN, ZA);</li>\n      <li>Megapime (MY, TH);</li>\n      <li>Pimcef (PE);</li>\n      <li>Pime (TH);</li>\n      <li>Pozineg (ET, QA);</li>\n      <li>Procepim (ID);</li>\n      <li>Protec (AE, KW, QA, SA);</li>\n      <li>Qpime (AE);</li>\n      <li>Rapime (ID);</li>\n      <li>Rovatim (PH);</li>\n      <li>Sanpime (PH);</li>\n      <li>Sefepim (MY);</li>\n      <li>Sefpime (PH, TH);</li>\n      <li>Sepime (PH);</li>\n      <li>Silex (PH);</li>\n      <li>Supecef (TW);</li>\n      <li>Superpime (BD);</li>\n      <li>Tetracef (BD);</li>\n      <li>Tsebopim (UA);</li>\n      <li>Tsepim (UA);</li>\n      <li>Uniceme (VN);</li>\n      <li>Unipim (BD);</li>\n      <li>Vidapime (PH);</li>\n      <li>Vifepime (VN);</li>\n      <li>Zepim (PH);</li>\n      <li>Zepime (PH);</li>\n      <li>Zepym (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allaouchiche B, Breilh D, Jaumain H, et al, &ldquo;Pharmacokinetics of Cefepime During Continuous Veno-Venous Hemodiafiltration,&rdquo; <i>Antimicrob Agents Chemother</i>, 1997, 41(11):2424-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/9371344/pubmed\" target=\"_blank\" id=\"9371344\">9371344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arguedas AG, Stutman HR, Zaleska M, et al, &ldquo;Cefepime. Pharmacokinetics and Clinical Response in Patients With Cystic Fibrosis,&rdquo; <i>Am J Dis Child</i>, 1992, 146(7):797-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/1496945/pubmed\" target=\"_blank\" id=\"1496945\">1496945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barbhaiya RH, Knupp CA, and Pittman KA, &ldquo;Effects of Age and Gender on Pharmacokinetics of Cefepime,&rdquo; <i>J Antimicrob Chemother</i>, 1992, 36(6):1181-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barradell LB and Bryson HM, &ldquo;Cefepime. A Review of Its Antibacterial Activity, Pharmacokinetic Properties, and Therapeutic Use,&rdquo; <i>Drugs</i>, 1994, 47(3):471-505.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/7514976/pubmed\" target=\"_blank\" id=\"7514976\">7514976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer KA, West JE, O'Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with <i>Pseudomonas aeruginosa</i> infections. <i>Antimicrob Agents Chemother</i>. 2013;57(7):2907-1292. doi: 10.1128/AAC.02365-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/23571547/pubmed\" target=\"_blank\" id=\"23571547\">23571547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26229122\"></a>Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span><span class=\"doi\">10.1093/cid/civ482</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer JL, Reed MD, Lemon E, et al, &ldquo;Pharmacokinetics (PK) of Cefepime in Pediatric Patients Administered Single and Multiple 50 mg/kg Doses Every 8 Hours by the Intravenous (I.V.) or Intramuscular (I.M.) Route,&rdquo; 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994, Orlando, Fl. Abs. A69.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cefepime hydrochloride and dextrose [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capparelli E, Hochwald C, Rasmussen M, et al, &quot;Population Pharmacokinetics of Cefepime in the Neonate,&quot; <i>Antimicrob Agents Chemother</i>, 2005, 49(7):2760-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/15980347/pubmed\" target=\"_blank\" id=\"15980347\">15980347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garrelts JC, Wagner DJ, &quot;The Pharmacokinetics, Safety, and Tolerance of Cefepime Administered as an Intravenous Bolus or as a Rapid Infusion,&quot; <i>Ann Pharmacother</i>, 1999, 33(12):1258-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/10630824/pubmed\" target=\"_blank\" id=\"10630824\">10630824</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lima-Rogel V, Medina-Rojas EL, Del Carmen Mil&aacute;n-Segovia R, et al, &quot;Population Pharmacokinetics of Cefepime in Neonates With Severe Nosocomial Infections,&quot; <i>J Clin Pharm Ther</i>, 2008, 33(3):295-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/18452417/pubmed\" target=\"_blank\" id=\"18452417\">18452417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malone RS, Fish DN, Abraham E, et al, &quot;Pharmacokinetics of Cefepime During Continuous Renal Replacement Therapy in Critically Ill Patients,&quot; <i>Antimicrob Agents Chemother</i>, 2001, 45(11):3148-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/11600370/pubmed\" target=\"_blank\" id=\"11600370\">11600370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maxipime (cefepime) [prescribing information]. Lake Forest, IL: Hospira; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. <i>J Crit Care</i>. 2010;25(1):69-77. doi: 10.1016/j.jcrc.2009.02.014.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/19427167/pubmed\" target=\"_blank\" id=\"19427167\">19427167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perez KK, Hughes DW, Maxwell PR, et al, &ldquo;Cefepime for Gram-Negative Bacteremia in Long-term Hemodialysis: A Single-Center Experience,&rdquo; <i>Am J Kidney Dis</i>, 2012, 59(5):740-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/22440135/pubmed\" target=\"_blank\" id=\"22440135\">22440135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saez-Llorens X, Castano E, Garcia R, et al, &ldquo;Prospective Randomized Comparison of Cefepime and Cefotaxime for Treatment of Bacterial Meningitis in Infants and Children,&rdquo; <i>Antimicrob Agents Chemother</i>, 1995, 39(4):937-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/7785999/pubmed\" target=\"_blank\" id=\"7785999\">7785999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yahav D, Paul M, Fraser A, et al, &ldquo;Efficacy and Safety of Cefepime: A Systematic Review and Meta-Analysis,&rdquo; <i>Lancet Infect Dis</i>, 2007, 7(5):338-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefepime-drug-information/abstract-text/17448937/pubmed\" target=\"_blank\" id=\"17448937\">17448937</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9215 Version 172.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20452476\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F147316\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F147353\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F147319\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F147337\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F147320\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F147321\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682524\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147294\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F147278\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F147298\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F147297\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25595582\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9645319\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147285\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147301\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147282\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298988\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147287\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147290\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5947925\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F147303\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F147292\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147281\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F147300\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323046\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F147304\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9215|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefepime-patient-drug-information\" class=\"drug drug_patient\">Cefepime: Patient drug information</a></li><li><a href=\"topic.htm?path=cefepime-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefepime: Pediatric drug information</a></li></ul></div></div>","javascript":null}